Highlights

* EMAS is challenging to differentiate from other epileptic encephalopathies
* Epileptic encephalopathies are typically pharmaco-resistant and have poor outcomes
* EMAS has better seizure and cognitive outcome if appropriate treatment is initiated
* There are no current established treatment recommendations
* This survey provides expert opinion for EMAS diagnosis, evaluation, and treatment